Subarachnoid Hemorrhage Recovery And Galantamine

• Status: Completed
• Trial end date: 2019-07-20
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the effects of the study drug--Galantamine-on patients with subarachnoid hemorrhage (SAH). The study will examine how patients with SAH will tolerate the study drug and how it may improve brain functioning in patients after SAH.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center, Houston
• Treatments: Galantamine

Criteria

Inclusion Criteria:

• Spontaneous subarachnoid hemorrhage

• Presentation to hospital within 72 hours of symptoms

• Fisher grade 3 hemorrhage (thick subarachnoid clot) on initial computed tomography (CT) scan

• Hunt and Hess grade 1-5 at time of randomization

• Presence of a cerebral aneurysm on computed tomographic angiography (CTA) or Angiogram for which clipping or coiling is possible

• Ability to obtain medication within 36 hours of presentation

Exclusion Criteria:

• subarachnoid hemorrhage (SAH) due to causes other than aneurysm rupture (trauma, arteriovenous malformation (AVM), mycotic aneurysms, Moyamoya)

• Pre-existing disability with modified Rankin Scale (mRS) score ≥2,

• Renal disease as defined by creatinine clearance less than 9 milliliters/min

• History of severe hepatic impairment (Child-Pugh score of 10-15)

• History of chronic obstructive pulmonary disease (COPD) or asthma

• History of dementia

• Co-morbid conditions likely to complicate therapy, including clinically significant arrhythmia, acquired immune deficiency syndrome (AIDS), autoimmune disease, malignancy, and expected mortality within 72 hours

• Expected mortality within 72 hours as determined by PI, treating neurointensivist and neurosurgeon. (Clinically manifested by no attempt at securing aneurysm)

• Females who are pregnant.